We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
151
DELISTED
Inozyme Pharma
INZY
$3.22M 0.03%
+188,704
New +$3.28M
IFRX icon
152
InflaRx
IFRX
$329M
$3.16M 0.03%
1,064,118
– –
KZR
153
DELISTED
Kezar Life Sciences
KZR
$3.03M 0.03%
+55,719
New +$3.16M
CVAC
154
CALL
DELISTED
CureVac
CVAC
$2.2M 0.02%
+30,000
New +$3M
LBPH
155
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.03M 0.01%
113,500
-186,500
-62% -$1.86M
MAPSW
156
CALL
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$954K 0.01%
+150,200
New +$931K
PPBT
157
Purple Biotech
PPBT
$2.73M
$86K ﹤0.01%
89
-68
-43% -$62.5K
ADVM
158
DELISTED
Adverum Biotechnologies
ADVM
– –
-550,114
Closed -$54.2M
ALHC icon
159
Alignment Healthcare
ALHC
$2.83B
– –
-800,000
Closed -$17.5M
AXSM icon
160
PUT
Axsome Therapeutics
AXSM
$10.4B
– –
-50,000
Closed -$2.83M
CMPS
161
Compass Pathways
CMPS
$1.9B
– –
-127,816
Closed -$4.71M
CVM icon
162
PUT
CEL-SCI Corp
CVM
$27.4M
– –
-3,333
Closed -$1.52M
FBRX icon
163
Forte Biosciences
FBRX
– –
-6,387
Closed -$5.47M
HAE icon
164
Haemonetics
HAE
$4.73B
– –
-852,000
Closed -$94.6M
HCAT icon
165
Health Catalyst
HCAT
$120M
– –
-179,598
Closed -$8.4M
INNV icon
166
InnovAge Holding
INNV
$1.47B
– –
-200,000
Closed -$5.16M
LAB icon
167
CALL
Standard BioTools
LAB
$252M
– –
-500,000
Closed -$2.26M
LRMR icon
168
Larimar Therapeutics
LRMR
$417M
– –
-617,245
Closed -$9.02M
MAPSW
169
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
– –
-150,200
Closed -$931K
MOH icon
170
Molina Healthcare
MOH
$10.4B
– –
-162,400
Closed -$38M
NTLA icon
171
Intellia Therapeutics
NTLA
$1.8B
– –
-72,500
Closed -$5.82M
NUVB icon
172
Nuvation Bio
NUVB
$2.34B
– –
-800,000
Closed -$8.36M
RNAC icon
173
Cartesian Therapeutics
RNAC
$290M
– –
-11,306
Closed -$1.53M
SANA icon
174
Sana Biotechnology
SANA
$1.18B
– –
-60,000
Closed -$2.01M
TVTX icon
175
Travere Therapeutics
TVTX
$6.19B
– –
-528,100
Closed -$13.2M
4 5 6
7
8

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.